An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
- 1 October 1997
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 133 (10), 1239-1242
- https://doi.org/10.1001/archderm.1997.03890460061007
Abstract
Actinic keratoses are potential precursors of invasive squamous cell carcinoma; therefore, treatment is often recommended. Current topical treatments may cause considerable discomfort, pain, or skin irritation. This study was established to explore the role, if any, of topical 3% diclofenac in 2.5% hyaluronic acid gel in the management of actinic keratoses.Keywords
This publication has 7 references indexed in Scilit:
- Epidemiology of solar keratosesBritish Journal of Dermatology, 2006
- Short-Term Intensive 5-Fluorouracil Treatment of Actinic KeratosesDermatologic Surgery, 1995
- Reduction of Solar Keratoses by Regular Sunscreen UseNew England Journal of Medicine, 1993
- Treatment with a non-steroidal anti-inflammatory agent delays the growth of spontaneous pulmonary metastases of a mammary adenocarcinoma of non-detected immunogenicityBritish Journal of Cancer, 1992
- Weekly pulse dosing: Effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratosesJournal of the American Academy of Dermatology, 1991
- A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neckJournal of the American Academy of Dermatology, 1991
- Regression of Head and Neck Carcinoma With a Prostaglandin-Synthesis InhibitorJAMA Otolaryngology–Head & Neck Surgery, 1981